EF Hutton Assumes HCW Biologics at Buy, Announces Price Target of $9
Portfolio Pulse from richadhand@benzinga.com
EF Hutton analyst Tony Butler assumes HCW Biologics (NASDAQ:HCWB) with a Buy rating and announces a price target of $9.
June 01, 2023 | 8:42 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HCW Biologics receives a Buy rating from EF Hutton analyst Tony Butler, with a price target of $9.
The Buy rating and $9 price target announced by EF Hutton analyst Tony Butler for HCW Biologics (NASDAQ:HCWB) is likely to have a positive short-term impact on the stock price. Investors may see this as a signal of confidence in the company's potential growth and performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100